SHIRE PLC: Shire successfully completes tender offer for ViroPharma

SHIRE PLC: Shire successfully completes tender offer for ViroPharma
Shire successfully completes tender offer for ViroPharma 
Dublin, Ireland - January 24, 2014 - Shire plc (LSE: SHP, NASDAQ: SHPG)
announces the successful completion of the tender offer for all of the
outstanding shares of ViroPharma (NASDAQ: VPHM). The tender offer expired at
midnight, New York City time, on Thursday, January 23, 2014 (one minute after
11:59 p.m., New York City time, on January 23, 2014), and was not extended. 
As of midnight on January 23, 2014, approximately 53,745,956 common shares of
ViroPharma (excluding 3,597,087 common shares of ViroPharma guaranteed to be
delivered within the next three NASDAQ trading days) had been validly tendered
and not withdrawn pursuant to the tender offer, representing approximately
79.5% of the outstanding common shares of ViroPharma. All shares that were
validly tendered and not withdrawn have been accepted for payment. 
Later today, Shire expects to complete the merger of ViroPharma with one of its
subsidiaries, and, in connection with the merger, all remaining common shares
of ViroPharma (excluding shares held by ViroPharma, Shire or certain of their
respective subsidiaries or holders who have properly demanded appraisal rights
under Delaware law) will be converted into the right to receive $50 per share
in cash, the same price that was paid in the tender offer. Following completion
of the merger, ViroPharma will become a wholly owned subsidiary of Shire and
its shares will cease to be traded on NASDAQ. 
For further information please contact: 
Investor Relations                                                              
                                                                           
Eric Rojas                              erojas@shire.com     +1 781 482 0999    
                                                                           
Sarah Elton-Farr                        seltonfarr@shire.com +44 1256 894157    
                                                                           
Media                                                                           
                                                                           
Jessica Mann                            jmann@shire.com      +44 1256 894 280   
                                                                           
Gwen Fisher                             gfisher@shire.com    +1 484 595 9836    
NOTES TO EDITORS 
Shire enables people with life-altering conditions to lead better lives. 
Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs. 
We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and
Internal Medicine and we are developing treatments for symptomatic conditions
treated by specialist physicians in other targeted therapeutic areas. 
www.shire.com 
FORWARD - LOOKING STATEMENTS 
Statements included in this announcement that are not historical facts are
forward-looking statements. Forward-looking statements involve a number of
risks and uncertainties and are subject to change at any time. In the event
such risks or uncertainties materialize, Shire's results could be materially
adversely affected. The risks and uncertainties include, but are not limited
to, that: 
* Shire's proposed acquisition of ViroPharma may not be consummated due to 


    the occurrence of an event, change or other circumstances that gives rise
    to the termination of the merger agreement;
      * a governmental or regulatory approval required for the proposed acquisition
    of ViroPharma may not obtained, or may be obtained subject to conditions
    that are not anticipated, or another condition to the closing of the
    proposed acquisition may not be satisfied;
      * ViroPharma may be unable to retain and hire key personnel and/or maintain
    its relationships with customers, suppliers and other business partners
    pending the consummation of the proposed acquisition by Shire, or
    ViroPharma's business may be disrupted by the proposed acquisition,
    including increased costs and diversion of management time and resources;
    and
      * difficulties in integrating ViroPharma into Shire may lead to the combined
    company not being able to realize the expected operating efficiencies, cost
    savings, revenue enhancements, synergies or other benefits at the time
    anticipated or at all;


and other risks and uncertainties detailed from time to time in Shire's or
ViroPharma's filings with the U.S. Securities and Exchange Commission,
including their respective most recent Annual Reports on Form 10-K. 
                                                                          
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX 
Press Release                                      
                                              
www.shire.com                                      
END 
-0- Jan/24/2014 11:31 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.